Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
genetic diseases
Pharma
Neurocrine's Prader-Willi med tied to possible safety concerns
A year and a half after the approval of Vykat XR, clinicians connected to the Prader-Willi syndrome community are flagging potential safety concerns.
Fraiser Kansteiner
Aug 13, 2026 9:40am
Neurocrine pays $2.9B for Soleno, its largest M&A deal ever
Apr 6, 2026 10:30am
Rhythm's Imcivree posts ph. 3 miss in rare genetic obesities
Mar 17, 2026 11:43am
Fierce Biotech
Senate hearing takes aim at FDA's rare disease review process
Feb 26, 2026 3:50pm
Quince explores options after ph. 3 rare disease flop
Jan 30, 2026 10:44am
Arrowhead strikes true with first FDA approval
Nov 18, 2025 3:44pm
